Alberta Health and Wellness Minister Ron Liepert announced details of the first phase of the province's major new pharmaceutical strategy on December 8.
Hearings start in the generic pharmaceutical industry's legal challenge of extended market monopolies for brand name drugs in the Federal Court of Canada.
Many CML patients today are living with side effects so strong that their quality of life is greatly reduced, according to a survey by the CML Society of Canada.
Pharmacists in London, England will receive authorization next year to supply women with the oral contraceptive pill over-the-counter-without the need for a doctor's prescription-as part of a new pilot project.
GlaxoSmithKline's Volibris is a new endothelin receptor antagonist for the treatment of idiopathic (primary) pulmonary arterial hypertension, as well as PAH associated with connective tissue disease.